Status:
COMPLETED
HFNC vs. NIV in Acute COPD Exacerbations
Lead Sponsor:
Haseki Training and Research Hospital
Conditions:
COPD Exacerbations
Acute Hypercapnic Respiratory Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The investigators investigated the efficacy and safety of High Flow Nasal Cannula (HFNC) at different flow rates compared to non-invasive ventilation (NIV) in patients presenting to the emergency depa...
Detailed Description
The patients were divided randomly into one of three study groups: NIV, HFNC-30, and HFNC-50. The investigators collected patient data, including demographic characteristics (age and sex), vital signs...
Eligibility Criteria
Inclusion
- \- patients age ≥18 years with a confirmed diagnosis of COPD who presented to the ED with exacerbations that did not respond to bronchodilator therapy
Exclusion
- patients aged younger than 18 years
- patients had an arterial pH ≤ 7.25;
- patients were in cardiopulmonary arrest;
- patients had unstable cardiac arrhythmias or hemodynamic instability;
- patients showed persistent hypoxemia despite supplemental oxygen therapy;
- patients were unconscious or uncooperative;
- patients could not protect their airway or manage secretions;
- patients had cardiogenic pulmonary edema, active hemoptysis, pneumothorax, recent upper respiratory tract/esophagus surgery, significant airway obstruction (e.g., laryngeal mass or tracheal tumor), active upper gastrointestinal bleeding, or facial trauma or deformities
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2024
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT06495086
Start Date
September 1 2023
End Date
May 1 2024
Last Update
July 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haseki Training and Research Hospital
Istanbul, Fatih, Turkey (Türkiye), 34265